Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
On Thursday, Tango Therapeutics Inc. (NASDAQ:TNGX) announced that it will discontinue the development of its TNG348 program.
週四，Tango Therapeutics Inc.（納斯達克股票代碼：TNGX）宣佈將停止其 TNG348 計劃的開發。
"Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand," said Barbara Weber, President and CEO.
“患者安全始終是我們的首要任務，根據 TNG348 劑量遞增研究的新數據，由於試驗中患者出現肝毒性，我們決定停止進一步開發該分子。儘管令人失望，但鑑於手頭的數據，我們認爲這是正確的決定。” 總裁兼首席執行官芭芭拉·韋伯說。
"We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year."
“我們將把資源和資本集中在我們現有的投資組合上，尤其是我們的 PRMT5 計劃。我們仍然致力於在今年下半年提供 TNG908 和 TNG462 的全面臨床更新，並對我們的能力充滿信心。”
TNG348 was being studied in a phase 1/2 clinical trial evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy as a single agent and in combination with AstraZeneca Plc's (NASDAQ:AZN) Lynparza (olaparib) in patients with BRCA1/2-mutant and other HRD+ (homologous recombination deficient) cancers.
TNG348 正在一項1/2期臨床試驗中進行研究，該試驗評估了作爲單一藥物以及與阿斯利康公司（納斯達克股票代碼：AZN）Lynparza（奧拉帕尼）聯合使用對BRCA1/2-突變體和其他 HRD+（同源重組缺乏）癌症患者的安全性、藥代動力學、藥效學和療效。
Grade 3/4 liver function abnormalities were observed in patients remaining on study longer than eight weeks, leading to the decision to terminate the program.
在研究時間超過八週的患者中觀察到3/4級肝功能異常，因此決定終止該項目。
No patient had yet received a combination of TNG348 and olaparib.
目前還沒有患者接受過 TNG348 和奧拉帕尼的聯合治療。
The company says the cash runway extended into 2027, and PRMT5 and CoREST clinical programs remain on track.
該公司表示，現金流延至2027年，PRMT5 和CoreST臨床項目仍在按計劃進行。
Earlier, Tango Therapeutics expected that its cash position of $344 million as of March 31, 2024, would provide a cash runway into late 2026.
此前，Tango Therapeutics預計，截至2024年3月31日，其3.44億美元的現金狀況將爲2026年底提供現金流。
Price Action: TNGX shares are trading 1.62% higher at $7.51 at the last check on Thursday.
價格走勢：在週四的最後一次支票中，TNGX股價上漲1.62％，至7.51美元。
Photo via Shutterstock
照片來自 Shutterstock